C
Connect Biopharmaceuticals
Connect Biopharmaceuticals, Ltd. is a clinical-stage company that discovers
About Connect Biopharmaceuticals
Connect Biopharma is a global clinical-stage biopharmaceutical company focused on creating innovative therapies for chronic inflammatory diseases driven by T cell biology. The company operates in key markets including China, the United States, Australia, and Europe, leveraging its expertise in functional cellular assays with T cells to discover and develop potent drug candidates. Connect Biopharma's business model revolves around the internal design and ownership of small molecules and antibodies, which are then advanced through clinical trials. Revenue is generated through the development and potential commercialization of these therapies, targeting conditions such as atopic dermatitis. The company serves patients suffering from chronic inflammatory diseases, aiming to improve their quality of life through cutting-edge medical research and development.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Suzhou Shi, China
- Open positions
- None listed
- Dealroom signal
- 61.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Autoimmune, Inflammatory Diseases, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Mar 2026 | $0 | — | Panacea Venture | ↗ |
| IPOOther financing | Mar 2021 | $191M | $191M | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Connect Biopharmaceuticals is 2.9K monthly website visits, down 85.5% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Cowin Capital
Series A3 investors entered at this stage
Qiming Venture Partners
NLVC- ACAdvantech Capital
Series B and later3 investors entered at this stage
RA Capital Management
Lilly Asia Ventures
Boxer Capital
Other known investors1 additional known investor
Panacea Venture
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Connect Biopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Connect Biopharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.